Turnstone Biologics (TSBX) Competitors $0.36 0.00 (-0.52%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$0.37 +0.00 (+1.05%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSBX vs. KZR, RNTX, BDRX, KALA, ESLA, EGRX, EYEN, SXTC, MRNS, and ALLKShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), Biodexa Pharmaceuticals (BDRX), KALA BIO (KALA), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), Eyenovia (EYEN), China SXT Pharmaceuticals (SXTC), Marinus Pharmaceuticals (MRNS), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Its Competitors Kezar Life Sciences Rein Therapeutics Biodexa Pharmaceuticals KALA BIO Estrella Immunopharma Eagle Pharmaceuticals Eyenovia China SXT Pharmaceuticals Marinus Pharmaceuticals Allakos Kezar Life Sciences (NASDAQ:KZR) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Do analysts recommend KZR or TSBX? Kezar Life Sciences currently has a consensus target price of $39.50, indicating a potential upside of 771.96%. Turnstone Biologics has a consensus target price of $0.45, indicating a potential upside of 23.90%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has more volatility and risk, KZR or TSBX? Kezar Life Sciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Does the media refer more to KZR or TSBX? In the previous week, Kezar Life Sciences had 2 more articles in the media than Turnstone Biologics. MarketBeat recorded 2 mentions for Kezar Life Sciences and 0 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -1.00 indicating that Turnstone Biologics is being referred to more favorably in the news media. Company Overall Sentiment Kezar Life Sciences Negative Turnstone Biologics Neutral Which has higher valuation & earnings, KZR or TSBX? Turnstone Biologics has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.73-$83.74M-$10.82-0.42Turnstone Biologics$19.31M0.44-$70.84M-$2.73-0.13 Do institutionals & insiders believe in KZR or TSBX? 67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is KZR or TSBX more profitable? Kezar Life Sciences' return on equity of -61.15% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -61.15% -50.27% Turnstone Biologics N/A -162.79%-124.10% SummaryKezar Life Sciences beats Turnstone Biologics on 8 of the 15 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.45M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-0.1320.8026.9720.11Price / Sales0.44286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book0.277.487.985.56Net Income-$70.84M-$55.04M$3.16B$248.40M7 Day Performance0.86%2.44%2.36%4.67%1 Month Performance-0.74%1.90%2.15%6.64%1 Year Performance-84.14%4.35%33.78%21.31% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics1.5663 of 5 stars$0.36-0.5%$0.45+23.9%-83.9%$8.45M$19.31M-0.1382KZRKezar Life Sciences4.015 of 5 stars$4.40-3.9%$39.50+797.7%-17.2%$32.15MN/A-0.4160RNTXRein TherapeuticsN/A$1.45+3.6%N/AN/A$32.12MN/A-0.519BDRXBiodexa PharmaceuticalsN/A$0.87+0.6%N/AN/A$31.79M$470K0.0020Upcoming EarningsKALAKALA BIO3.4674 of 5 stars$4.84+1.7%$13.50+178.9%-24.2%$31.22M$3.89M-0.5930News CoverageHigh Trading VolumeESLAEstrella Immunopharma2.2166 of 5 stars$0.86-10.3%$16.00+1,758.7%-29.7%$31.14MN/A-3.31N/APositive NewsGap DownEGRXEagle PharmaceuticalsN/A$2.36-18.6%N/A-45.9%$30.65M$257.55M0.00100EYENEyenovia1.0008 of 5 stars$10.56+1.7%$2.00-81.1%-77.3%$30.41M$60K-0.1840SXTCChina SXT Pharmaceuticals0.1511 of 5 stars$1.92+11.0%N/A-79.1%$30.39M$1.82M0.0090News CoverageMRNSMarinus Pharmaceuticals2.3196 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110ALLKAllakos3.0262 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190 Related Companies and Tools Related Companies Kezar Life Sciences Competitors Rein Therapeutics Competitors Biodexa Pharmaceuticals Competitors KALA BIO Competitors Estrella Immunopharma Competitors Eagle Pharmaceuticals Competitors Eyenovia Competitors China SXT Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Allakos Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSBX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSBX Stock Alerts